Phase I Trial of R115777 and OSI-774 in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Erlotinib (Primary) ; Tipifarnib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jan 2014 Planned End Date changed to 1 May 2008 as the status is active, no longer recruiting as reported in ClinicalTrials.gov record.
- 29 Dec 2006 Status change
- 24 Sep 2005 New trial record.